Factor Xa inhibitors are a type of anticoagulant that work by selectively and reversibly blocking the activity of clotting factor Xa, preventing clot formation. They affect both factor Xa within the blood and within a preexisting clot. They do not affect platelet aggregation. They are used for the treatment and prevention of deep vein thrombosis and acute pulmonary embolism, and to reduce the risk of stroke and embolism in people with nonvalvular atrial fibrillation.
Factor Xa is generated by both the extrinsic and intrinsic coagulation pathways and is responsible for activating prothrombin to thrombin. Factor Xa inhibitors have predictable anticoagulant effects and do not require routine monitoring, unlike some other anticoagulants.
Apixaban, edoxaban, fondaparinux, and rivaroxaban are all Factor Xa inhibitors.
Name | Updated |
---|---|
Fondaparinux (Fondaparinux [ fon-dap-a-rin-ux ]) | 14-Aug-2023 |
Edoxaban (Edoxaban [ e-dox-a-ban ]) | 13-Aug-2023 |
Rivaroxaban (Rivaroxaban [ riv-a-rox-a-ban ]) | 12-Aug-2023 |
Xarelto starter pack (Rivaroxaban [ riv-a-rox-a-ban ]) | 14-Jul-2023 |
Savaysa (Edoxaban [ e-dox-a-ban ]) | 14-Jul-2023 |
Bevyxxa (Betrixaban [ be-trix-a-ban ]) | 13-Jul-2023 |
Arixtra (Fondaparinux [ fon-dap-a-rin-ux ]) | 12-Jul-2023 |
Xarelto (Rivaroxaban [ riv-a-rox-a-ban ]) | 12-Jul-2023 |
Eliquis (Apixaban [ a-pix-a-ban ]) | 10-Jul-2023 |
Apixaban (Apixaban [ a-pix-a-ban ]) | 10-Jul-2023 |